Market Scenario

Leuprolide acetate is a synthetic gonadotropin-releasing hormone which is a synthetic nonapeptide acetate salt, used in men to treat symptoms of prostate cancer, and in women to treat symptoms of endometriosis (overgrowth of uterine lining outside of the uterus) or uterine fibroids. This salt binds receptors of the gonadotropin-releasing hormone to shows a therapeutic effect. leuprolide acetate is a cancer chemotherapy drug.  Addition to this, leuprolide acetate is presently being tested for the treatment of Alzheimer's disease, polycystic ovary syndrome, functional bowel disease, short stature, premenstrual syndrome and even as an alternative for contraception. According to Alzheimer organization Alzheimer is the 6^th largest leading cause of death in United States and it is expected that by, 2050 this number can increase to 14 million which can act as a major driving factor for leuprolide market. In 2016, National cancer institute estimated 15.5 million cancer survivors in US and predicted to increase to 20.3 million in 2026 which can promote the Leuprolide acetate market Players in US. Additionally, the increasing geriatric population, ageing and growing pharmaceutical and healthcare sectors boost the market growth. However, factors like low healthcare expenditure, and presence of alternative treatments in the market are likely to hinder the market growth during the forecasted period.

Leuprolide Acetate Market-Competitive Landscape

The global Leuprolide Acetate market overview is characterized by the presence of several well-established and small players, the market appears to be highly competitive and fragmented. Multinational players are increasingly expanding their regional presence in the developing economy, results increase in competition for regional vendors, especially in terms of features such as product differentiation, diverse product portfolios, new trends and quality. The well-established market players are Takeda Pharmaceutical Company Limited, Golrang pharmaceutical investment (GPI), Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Company Limited is a pharmaceutical company established in June 1781, headquartered in Japan. Takeda involved in research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. It operates in three segments: Prescription Drug, Consumer Healthcare, and Other. Takeda Pharmaceutical is also involved in clinical diagnostics, chemical products, and other businesses. In September 2014, Takeda Pharmaceutical announced that they have submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for Leupin a treatment for prostate cancer and premenopausal breast cancer.

Regional Analysis

Geographically, the global practice analytics market is segmented into the Americas, Europe, Asia-Pacific and Middle East & Africa. North America is anticipated to hold the largest market share during the forecasted period. The major factor influencing the growth of the market include increase in the ageing of population, polycystic ovary syndrome and Alzheimer's disease. Investment in Research and development also drive the demand for leuprolide acetate market in this region. According to Alzheimer organization Alzheimer disease is the 6^th largest leading cause of death in United States. It was stated that 5.7 million of Americans population is living with Alzheimer. By, 2050 this number is projected to increase by nearly 14 million. According, to Centers of Disease control and Prevention (CDC) Polycystic Ovary Syndrome (POS) is one of the major causes of female infertility, with 6% to 12% (as many as 5 million) of US women of reproductive age. POS is a insulin resistant in which body make insulin but do not use it completely. As per National institute of health (NIH), in 2015, it was estimated 3,120,176 men living with prostate cancer in the United States. Also, prescribed for the women dealing with endometriosis and Uterine Fibroids, which are one of the most complicated and painful diseases related to female reproductive system. Increase medical professionals has resulted in demand for better standards and quality end products which will further influence the demand in the leuprolide acetate market in the North American region.

 Europe is the second largest market followed by Asia-Pacific. The market in this region is expected to witness growth due to rising prevalence of prostate cancer. According to the Cancer Research UK, in 2015, 47151 patients suffered from prostate cancer. Thus driving market growth.

Asia Pacific is estimated to be the fastest growing region and holds the third largest market for leuprolide acetate due to premenstrual syndrome and premenstrual dysphoric (PMS) disorder. Prevalence of PMS among college students is similar to other studies from Asia. According to National Center of Biotechnology Information in India about 27.7% of female population falls in the 15-29 years age-group which is a major driving factor for Leuprolide Acetate Market. The increase in the population of India and China are the major drivers for the market growth.

The Middle East & Africa holds the least market share in leuprolide mark because of poor economy, low government policies, lack of awareness, low per capita income and poor availability of healthcare services.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com